CYBERLEGs Plus Plus (CLs++) Consortium will address 4 specific innovation objectives:


Further developments of the existing CYBERLEGs hardware modules, namely the 2-degree-of-freedom active transfemoral prosthesis, the active wearable orthotic devices, and the wearable sensory apparatus


Further developments of the existing multi-layered CYBERLEGs control system, to enhance its reliable use in real-life scenarios


Carrying out two multi-centre clinical studies, that validate the therapeutic potentialities and the economic viability of a robotic ortho-prosthesis which restores the amputees’ locomotion abilities in scenarios of activities of daily living


Implementation of a 3-phase strategy to foster the start of the market exploitation within the time frame of the CLs++ project.

The project focuses on the demonstration in an operational environment from both the technical and economic viability view point of a modular robotics technology for healthcare, with the ultimate goal of fostering its market exploitation. The Consortium will achieve the main innovation objectives thanks to the strong synergy between players from academia, clinical end-users, as well as robotics and healthcare industry.

The CLs++ project results will have a significant impact in different fields:

  • Scientific & Technological Impact (i) increasing the market-readiness of CLs robotics technology; (ii) assessing the efficacy and safety of CLs++ technology; (iii) assessing the economic viability and business planning of the CLs++ technology
  • Health-care domain Impact (i) increasing mobility of dysvascular transfemoral amputees; (ii) providing new knowledge and standard protocol for early treatment of dysvascular patients; (iii) extending the adoption of CLs++ technologies to other lower-limb impairments
  • Societal Impact with the (i) growth of competitive small and mid-scale robotics companies in Europe; (ii) deployment of robotics technologies in new application domains.